11/12
07:30 am
pcvx
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
Medium
Report
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
11/10
05:31 am
pcvx
1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst [Yahoo! Finance]
Low
Report
1 Vanguard ETF That Could Soar 27.1% Before the End of 2024, According to a Top Wall Street Analyst [Yahoo! Finance]
11/7
06:58 am
pcvx
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]
Medium
Report
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely [Yahoo! Finance]
11/6
10:18 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/6
08:07 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.
Medium
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $140.00 price target on the stock.
11/6
12:16 am
pcvx
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight [Yahoo! Finance]
Medium
Report
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight [Yahoo! Finance]
11/5
04:01 pm
pcvx
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
11/1
09:29 am
pcvx
Should You Consider Investing in Vaxcyte (PCVX)? [Yahoo! Finance]
Low
Report
Should You Consider Investing in Vaxcyte (PCVX)? [Yahoo! Finance]
9/23
08:08 am
pcvx
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar? [Yahoo! Finance]
Medium
Report
Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar? [Yahoo! Finance]
9/11
04:05 pm
pcvx
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
Low
Report
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
9/10
10:04 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Mizuho from $113.00 to $163.00. They now have an "outperform" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Mizuho from $113.00 to $163.00. They now have an "outperform" rating on the stock.
9/8
09:56 am
pcvx
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027 [Seeking Alpha]
Medium
Report
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027 [Seeking Alpha]
9/6
04:06 pm
pcvx
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy [Seeking Alpha]
Medium
Report
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy [Seeking Alpha]
9/6
04:05 pm
pcvx
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Medium
Report
Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
9/4
11:58 pm
pcvx
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
Low
Report
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
9/4
10:32 am
pcvx
Company News for Sep 4, 2024 [Yahoo! Finance]
Medium
Report
Company News for Sep 4, 2024 [Yahoo! Finance]
9/4
08:06 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Bank of America Co. from $101.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Bank of America Co. from $101.00 to $140.00. They now have a "buy" rating on the stock.
9/3
06:26 pm
pcvx
Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales [Yahoo! Finance Canada]
Low
Report
Vaccine Maker Raising $1 Billion Leads Post-Holiday Share Sales [Yahoo! Finance Canada]
9/3
06:19 pm
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Leerink Partners from $106.00 to $153.00. They now have an "outperform" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Leerink Partners from $106.00 to $153.00. They now have an "outperform" rating on the stock.
9/3
06:19 pm
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $129.00. They now have a "buy" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Jefferies Financial Group Inc. from $108.00 to $129.00. They now have a "buy" rating on the stock.
9/3
04:59 pm
pcvx
Vaxcyte commences proposed public offering of common stock & pre-funded warrants [Seeking Alpha]
Low
Report
Vaxcyte commences proposed public offering of common stock & pre-funded warrants [Seeking Alpha]
9/3
04:19 pm
pcvx
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Low
Report
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
9/3
04:01 pm
pcvx
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Low
Report
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
9/3
02:08 pm
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at BTIG Research from $98.00 to $160.00. They now have a "buy" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at BTIG Research from $98.00 to $160.00. They now have a "buy" rating on the stock.
9/3
02:08 pm
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Needham & Company LLC from $95.00 to $140.00. They now have a "buy" rating on the stock.
Low
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Needham & Company LLC from $95.00 to $140.00. They now have a "buy" rating on the stock.